J&J to acquire Momenta for $6.5 billion
The move will expand Janssen’s presence in autoimmune diseases
Read More
Tag: Momenta
Shire steps away from biosimilars
Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
